Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05715918
Other study ID # ? VKI-D-III-12/21
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date April 1, 2022
Est. completion date February 1, 2024

Study information

Verified date February 2023
Source Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, double-blind, placebo controlled, multi-center clinical trials of the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified vaccine against COVID-19, manufactured by FSBSI "Chumakov FSC R&D IBP RAS", of childrens aged 12-17" (Clinical trials, phase III). Study purpose is to assess the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified coronavirus vaccine of chidrens aged 12-17


Description:

Recruitment of volunteers will be competitive. A maximum of 450 children aged 12 to 17 years inclusive will be screened in the study, of which it is planned to include and randomize 300 children who meet the criteria for inclusion in the study and do not have non-inclusion criteria, data on which will be used for subsequent safety and immunogenicity analysis. Group 1 - 150 volunteers who will be vaccinated with the Nobivac vaccine twice with an interval of 21 days intramuscularly. Group 2 - 150 volunteers who will receive a placebo twice with an interval of 21 days intramuscularly. In case of withdrawal of volunteers from the study, their replacement is not provided.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 300
Est. completion date February 1, 2024
Est. primary completion date December 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria: - Volunteers must meet the following inclusion criteria: Type of participants • Healthy volunteers. Age at the time of signing the Informed Consent • from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days). Paul • Male or female. Reproductive characteristics - For girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). - For young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). Young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). Research procedures - Written Informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial. - Volunteers who are able to fulfill Protocol requirements (i.e. answer phone calls, fill out a Self-observation Diary, come to control visits). Non-inclusion criteria: - Volunteers cannot be included in the study if any of the following criteria are present: SARS-CoV-2 infection - A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months. - History of contacts with confirmed or suspected cases of SARS-CoV-2 infection within 14 days prior to vaccination. - Positive IgM or IgG to SARS-CoV-2 detected on Screening. - Positive PCR test for SARS-CoV-2 at Screening / before vaccination. Diseases or medical conditions - Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination. - Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.). - Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis. - The axillary temperature at the time of vaccination is more than 37.0 ° C. - Positive blood test for HIV, syphilis, hepatitis B/C. - Acute infectious diseases (recovery earl Exclusion Criteria: - • Withdrawal of Informed consent by a volunteer and/or a parent of a volunteer; - The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol; - Availability of inclusion/non-inclusion criteria before vaccination; - Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study; - The established fact of pregnancy before the second vaccination; - Taking unauthorized medications (see section 6.2); - The volunteer's incompetence with the study procedures; - The volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation; - For administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as in case of gross violations of the protocol that may affect the results of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Vaccine for intramuscular injection
Volunteers ( Group 1 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
Other:
Placebo comparator (without active ingredient) for intramuscular injection
Volunteers ( Group 2 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml

Locations

Country Name City State
Russian Federation State Budgetary Health Institution of the Moscow Region "Elektrostal Central City Hospital" Elektrostal Moscow
Russian Federation Kirov Regional State Budgetary Health Institution "Kirov Regional Children's Clinical Hospital" Kirov
Russian Federation FSBSI Chumakov FSC R&D IBP RAS Moscow
Russian Federation St. Petersburg State Budgetary Health Institution "Children's City Polyclinic No. 45 of the Nevsky District" Saint Petersburg

Sponsors (1)

Lead Sponsor Collaborator
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Geometric mean titer (GMT) The percentage of volunteers with an increase in geometric mean titer of specific antibodies (GMT) on day 21 after the second dose of vaccine / placebo in the virus neutralization test and ELISA. 21 days
Primary Geometric mean titer (GMT) The multiplicity of the increase in the geometric mean titer of specific antibodies (GMT) for 21 days after the second vaccination in the viral neutralization reaction and ELISA reaction. 21 days
Primary The level of seroconversion The level of seroconversion (titer of specific antibodies = 4 times) on 21 days after the second vaccination in the reaction of virusneutralization and ELISA reaction 21 days
Secondary Geometric mean titer (GMT) The mean geometric titer of specific antibodies (GMT) 12 and 24 weeks after the second vaccination in the viral neutralization reaction and ELISA reaction. 24 weeks
Secondary Geometric mean titer (GMT) The multiplicity of the increase in the geometric mean titer of specific antibodies (GMT) 12 and 24 weeks after the second vaccination in the viral neutralization reaction and ELISA reaction. 24 weeks
Secondary The level of seroconversion The level of seroconversion (titer of specific antibodies = 4 times) 12 and 24 weeks after the second vaccination in the viral neutralization reaction and ELISA reaction. 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Completed NCT00401505 - Rubella Susceptibility in Multiparous Women
Recruiting NCT05054621 - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule Phase 2
Completed NCT05083065 - Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
Recruiting NCT05085145 - Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV Phase 4
Completed NCT05046548 - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Phase 1/Phase 2
Completed NCT01961947 - Study of ASP7374, Cell-culture-derived Influenza Vaccine Phase 3
Completed NCT01961960 - A Study to Evaluate Intramuscular ASP7374 Phase 3
Completed NCT00401700 - Influenza Vaccine Postpartum Questionnaire
Completed NCT03300050 - Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine Phase 1
Completed NCT01015703 - Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers Phase 1
Completed NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Phase 4
Active, not recruiting NCT05099965 - Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) Phase 2
Recruiting NCT04638985 - Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR Phase 4
Recruiting NCT06136832 - Pneumonia Vaccine Education Intervention Study N/A
Active, not recruiting NCT04741828 - Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Phase 2/Phase 3
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Completed NCT03714737 - Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese Phase 3
Completed NCT04664309 - Understanding Immunity to the COVID-19 Vaccines